Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Angina

Trial Information

Ranolazine and Pulmonary Hypertension

Official Title: Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension

Summary

The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL). For this study, you will be asked to perform several tests in order to determine if your heart function, exercise capacity, chest pain and QOL have improved after 3 months of treatment with ranolazine. Ranolazine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of angina.

Phase: Phase 3

Sponsor: Northwestern University

Locations (1)

Country State City Zip Facility and Contact
United States Illinois Chicago 60611 Northwestern University
Sanjiv Shah, MD
312-926-2926

Sanjiv Shah, MD
Principal Investigator

NCT ID:NCT01174173

Date Last Changed: June 28, 2012